Free tool
FAERS Monitor: Exforge
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021990 or its brand name (Exforge, Amlodipine Besylate, Valsartan). Reports on generic versions are filed under their own applications.
Reports
11,054
Serious
9,506
86% of reports
Hospitalization
3,884
Death reported
1,273
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- blood pressure increased662
- hypertension589
- drug ineffective553
- dizziness495
- malaise471
- death470
- fatigue445
- fall430
- headache401
- dyspnoea364
- oedema peripheral354
- diabetes mellitus353
- diarrhoea345
- cerebrovascular accident343
- nausea327
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 58 |
| 2008 | 276 |
| 2009 | 478 |
| 2010 | 542 |
| 2011 | 873 |
| 2012 | 1,107 |
| 2013 | 885 |
| 2014 | 812 |
| 2015 | 776 |
| 2016 | 683 |
| 2017 | 593 |
| 2018 | 759 |
| 2019 | 612 |
| 2020 | 599 |
| 2021 | 548 |
| 2022 | 469 |
| 2023 | 347 |
| 2024 | 238 |
| 2025 | 214 |
| 2026 | 185 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,105 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| diabetes mellitusSignal | 353 | 8.8 | 8.0 | 2,447 |
| blood pressure increasedSignal | 662 | 8.3 | 7.7 | 4,236 |
| oedema peripheralSignal | 354 | 5.5 | 5.0 | 1,316 |
| hypertensionSignal | 589 | 5.3 | 4.9 | 2,068 |
| cerebrovascular accidentSignal | 343 | 3.9 | 3.5 | 728 |
| fallSignal | 430 | 2.5 | 2.2 | 377 |
| malaiseSignal | 471 | 2.0 | 1.9 | 255 |
| dizziness | 495 | 1.9 | 1.7 | 211 |
| dyspnoea | 364 | 1.2 | 1.1 | 15 |
| headache | 401 | 1.2 | 1.1 | 16 |
| fatigue | 445 | 1.1 | 1.0 | 3 |
| death | 470 | 1.0 | 1.0 | 1 |
| diarrhoea | 345 | 1.0 | 0.9 | 0 |
| drug ineffective | 553 | 0.8 | 0.7 | 30 |
| nausea | 327 | 0.8 | 0.7 | 20 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.